A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

Sponsor
Eli Lilly and Company
Study ID
NCT04591626
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dulaglutide — DRUG
    Administered SC
  • Placebo — DRUG
    Administered SC
  • Insulin Glargine — DRUG
    Administered SC

Study Details

The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.

Key Dates

Start date
Dec 7, 2020
Status verified
Apr 2023
Primary completion
Apr 28, 2022
Completion
Apr 28, 2022

Study Design

Enrollment
291 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1.5 Milligrams (mg) Dulaglutide
    Participants received 1.5 mg Dulaglutide administered once weekly (QW) subcutaneously (SC) as add-on to titrated treat-to-target (TTT) dose of Insulin Glargine given SC, along with metformin and/or acarbose.
  • Placebo Comparator: Placebo
    Participants received placebo administered QW SC as add-on to titrated TTT dose of insulin glargine given SC, along with metformin and/or acarbose.

Primary Outcome Measure

Change From Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, Week 28 ]

Related Studies